Actively Recruiting

Early Phase 1
Age: 18Years - 75Years
All Genders
ID05771675

Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

Led by Cedars-Sinai Medical Center · Updated on 2026-02-27

90

Participants Needed

5

Research Sites

26 weeks

Total Duration

On this page

Sponsors

C

Cedars-Sinai Medical Center

Lead Sponsor

U

United States Department of Defense

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of simvastatin in adults with Recurrent Acute Pancreatitis (RAP) and Chronic Pancreatitis (CP), conditions that currently have no available treatments and cause persistent abdominal pain. This pilot study aims to test the feasibility and acceptability of a clinical trial to see if simvastatin can improve quality of life and slow disease progression by restoring pancreatic cell health and reducing inflammation. RAP is considered a form of pancreatitis that precedes CP. Participants will be randomly assigned in a 2:1 ratio to receive either simvastatin 40mg capsules or matching placebo capsules once daily for 6 months. The study includes a 24-month recruitment period, and the treatment phase lasts 6 months. Outcomes will be measured at the start, 3 months, 6 months, and then 6 months after stopping treatment, totaling one year of participant involvement. During the study, participants will complete assessments related to pain and health-related quality of life, while adherence and side effects will be closely monitored. Blood biomarkers will also be measured to provide biochemical evidence of treatment effects. The primary goal is to assess feasibility with targets for enrollment, adherence, side effects, and acceptability. Participants will be followed for 12 months unless they withdraw or are withdrawn for safety reasons.

CONDITIONS

Brief Title

Simvastatin Treatment to Improve Patient-reported Outcomes in Patients With Chronic Pancreatitis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Provision of signed and dated informed consent form
  • Willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18-75 at time of enrollment
  • Diagnosis of Recurrent Acute or Chronic Pancreatitis not due to gallstones, medications, trauma, or autoimmune pancreatitis
  • Ability to take oral medication and willingness to follow dosing regimen
  • For females of reproductive potential: use of effective contraception before and during study, and for one month after
  • For males of reproductive potential: use of effective contraception with partner before and during study, and for one month after
  • No prior pancreatic surgery
  • No current statin use within 6 months
Not Eligible

You will not qualify if you...

  • Pregnancy or lactation
  • History of autoimmune, medication-caused, or traumatic pancreatitis
  • Presence of primary pancreatic tumors or pancreatic metastasis
  • History of solid organ transplant or HIV/AIDS
  • Known isolated pancreatic exocrine insufficiency without other inclusion criteria
  • Use of specific interacting medications like itraconazole, ketoconazole, erythromycin, and others
  • Current simvastatin use within past 6 months
  • Medical or psychiatric illnesses or substance abuse that would interfere with study participation
  • Active liver disease
  • Known pregnancy or failure to have negative pregnancy test if of childbearing potential
  • Currently incarcerated
  • Inability to comply with study activities

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 6 months

Participants take simvastatin or placebo capsules once daily for 6 months to evaluate effects on pain and quality of life.

Visits at baseline, 3 months, and 6 months during treatment

Follow-up

Duration - 6 months

Participants are monitored for 6 months after treatment ends to assess ongoing effects and safety.

1 visit at 6 months post-treatment

Trial Site Locations

Total: 5 locations

1

University of Southern California

Los Angeles, California, United States, 90033

Actively Recruiting

2

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048

Actively Recruiting

3

Stanford University

Stanford, California, United States, 94305

Actively Recruiting

4

Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

5

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

Loading map...

Research Team

A

Arax Shanlian

A

Arax Shanlian

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Pilot Clinical Trial of Paricalcitol for Chronic Pancreati...

Chronic Pancreatitis

Actively Recruiting

1 location

Open-Label Study of Human Secretin Injection on Pancreatic F...

Exocrine Pancreatic Insufficiency

Actively Recruiting

1 location

A Multicenter Clinical Study on AI-Powered Precision Decisio...

Pancreatic Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here